TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE
6.1. Overview
6.2. Oral Iron Therapy
6.3. Parenteral Iron Therapy
6.4. Red Blood Cell Transfusion
7. GLOBAL IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY END USER
7.1. Overview
7.2. Hospitals
7.3. Clinics
7.4. Home Healthcare
8. GLOBAL IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY REGION
8.1. Overview
8.1. North America
8.1.1. US
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. France
8.2.3. UK
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia-Pacific
8.3.1. China
8.3.2. India
8.3.3. Japan
8.3.4. South Korea
8.3.5. Australia
8.3.6. Rest of Asia-Pacific
8.4. Rest of the World
8.4.1. Middle East
8.4.2. Africa
8.4.3. Latin America
9. COMPETITIVE LANDSCAPE
9.1. Overview
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Global Iron Deficiency Anemia Treatment Market,
9.5. Competitive Benchmarking
9.6. Leading Players in Terms of Number of Developments in the Global Iron Deficiency Anemia Treatment Market,
9.7. Key developments and Growth Strategies
9.7.1. New ProductLaunch/Service Deployment
9.7.2. Merger &Acquisitions
9.7.3. Joint Ventures
9.8. Major Players Financial Matrix
9.8.1. Sales & Operating Income,2022
9.8.2. Major Players R&D Expenditure.2022
10. COMPANY PROFILES
10.1. Abbvie Inc.;
10.1.1. Company Overview
10.1.2. Financial Overview
10.1.3. Products Offered
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. Akebia Therapeutics Inc.;
10.2.1. Company Overview
10.2.2. Financial Overview
10.2.3. Products Offered
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. AMAG Pharmaceuticals Inc. (Covis Group S.r.l.);
10.3.1. Company Overview
10.3.2. Financial Overview
10.3.3. Products Offered
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. Daiichi Sankyo Company;
10.4.1. Company Overview
10.4.2. Financial Overview
10.4.3. Products Offered
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Pharmacosmos AS;
10.5.1. Company Overview
10.5.2. Financial Overview
10.5.3. Products Offered
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. Sanofi SA;
10.6.1. Company Overview
10.6.2. Financial Overview
10.6.3. Products Offered
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. Johnson and Johnson;
10.7.1. Company Overview
10.7.2. Financial Overview
10.7.3. Products Offered
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. Fresenius SE & Co. KGaA;
10.8.1. Company Overview
10.8.2. Financial Overview
10.8.3. Products Offered
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. ViforPharma Ltd.;
10.9.1. Company Overview
10.9.2. Financial Overview
10.9.3. Products Offered
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. Rockwell Medical, Inc.
10.10.1. Company Overview
10.10.2. Financial Overview
10.10.3. Products Offered
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies
10.11. Akorn Operating Company LLC;
10.11.1. Company Overview
10.11.2. Financial Overview
10.11.3. Products Offered
10.11.4. Key Developments
10.11.5. SWOT Analysis
10.11.6. Key Strategies
10.12. Shield Therapeutics.
10.12.1. Company Overview
10.12.2. Financial Overview
10.12.3. Products Offered
10.12.4. Key Developments
10.12.5. SWOT Analysis
10.12.6. Key Strategies
11. APPENDIX
11.1. References
11.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL IRON DEFICIENCY ANEMIA TREATMENT MARKET, SYNOPSIS, 2018-2032
TABLE 2 GLOBAL IRON DEFICIENCY ANEMIA TREATMENT MARKET, ESTIMATES &FORECAST, 2018-2032(USD BILLION)
TABLE 3 GLOBAL IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 4 GLOBAL IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY END USER, 2018-2032 (USD BILLION)
TABLE 5 NORTH AMERICA: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY END USER, 2018-2032 (USD BILLION)
TABLE 7 US: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 8 US: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY END USER, 2018-2032 (USD BILLION)
TABLE 9 CANADA: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 10 CANADA: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY END USER, 2018-2032 (USD BILLION)
TABLE 1 EUROPE: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 2 EUROPE: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 3 GERMANY: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE,2018-2032 (USD BILLION)
TABLE 4 GERMANY: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 5 FRANCE: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 6 FRANCE: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 7 ITALY: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 8 ITALY: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 9 SPAIN: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 10 SPAIN: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 11 UK: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 12 UK: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 13 REST OF EUROPE: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 14 REST OF EUROPE: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 15 ASIA-PACIFIC: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 16 ASIA-PACIFIC: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 17 JAPAN: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 18 JAPAN: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 19 CHINA: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 20 CHINA: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 21 INDIA: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 22 INDIA: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 23 AUSTRALIA: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 24 AUSTRALIA: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 25 SOUTH KOREA: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 26 SOUTH KOREA: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 27 REST OF ASIA-PACIFIC: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 28 REST OF ASIA-PACIFIC: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 29 REST OF THE WORLD: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 30 REST OF THE WORLD: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 31 MIDDLE EAST: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 32 MIDDLE EAST: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 33 AFRICA: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 34 AFRICA: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 35 LATIN AMERICA: IRON DEFICIENCY ANEMIA TREATMENT MARKET,BY THERAPY TYPE, 2018-2032 (USD BILLION)
TABLE 36 LATIN AMERICA: IRON DEFICIENCY ANEMIA TREATMENT MARKET, BY END USER, 2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL IRON DEFICIENCY ANEMIA TREATMENT MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL IRON DEFICIENCY ANEMIA TREATMENT MARKET
FIGURE 4 GLOBAL IRON DEFICIENCY ANEMIA TREATMENT MARKET, SHARE (%), BY THERAPY TYPE, 2022
FIGURE 5 GLOBAL IRON DEFICIENCY ANEMIA TREATMENT MARKET, SHARE (%), BY END USER, 2022
FIGURE 6 GLOBAL IRON DEFICIENCY ANEMIA TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 7 NORTH AMERICA: IRON DEFICIENCY ANEMIA TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 8 EUROPE: IRON DEFICIENCY ANEMIA TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 ASIA-PACIFIC: IRON DEFICIENCY ANEMIA TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 REST OF THE WORLD: IRON DEFICIENCY ANEMIA TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 GLOBAL IRON DEFICIENCY ANEMIA TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 12 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 ABBVIE INC.: SWOT ANALYSIS
FIGURE 14 AKEBIA THERAPEUTICS INC.:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 AKEBIA THERAPEUTICS INC.:SWOT ANALYSIS
FIGURE 16 AMAG PHARMACEUTICALS INC. (COVIS GROUP S.R.L.):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 AMAG PHARMACEUTICALS INC. (COVIS GROUP S.R.L.):SWOT ANALYSIS
FIGURE 18 DAIICHI SANKYO COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 DAIICHI SANKYO COMPANY:SWOT ANALYSIS
FIGURE 20 PHARMACOSMOS AS.:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 PHARMACOSMOS AS.:SWOT ANALYSIS
FIGURE 22 SANOFI SA:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 SANOFI SA:SWOT ANALYSIS
FIGURE 24 JOHNSON AND JOHNSON: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 JOHNSON AND JOHNSON: SWOT ANALYSIS
FIGURE 26 FRESENIUS SE & CO. KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 FRESENIUS SE & CO. KGAA: SWOT ANALYSIS
FIGURE 28 VIFORPHARMA LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 VIFORPHARMA LTD.: SWOT ANALYSIS
FIGURE 30 ROCKWELL MEDICAL, INC.:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 ROCKWELL MEDICAL, INC.:SWOT ANALYSIS
FIGURE 32 AKORN OPERATING COMPANY LLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 AKORN OPERATING COMPANY LLC: SWOT ANALYSIS
FIGURE 34 SHIELD THERAPEUTICS:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 SHIELD THERAPEUTICS:SWOT ANALYSIS